[Treatment of pulmonary hypertension associated with connective tissue disease].
Pulmonary hypertension is the most ominous complication of connective tissue diseases and its treatment has been a big challenge to clinicians. Vasodilators including epoprostenol (prostacyclin), bosentan (endothelin-receptor antagonist), and a sildenafil (phosphodiesterase type 5 inhibitor) have recently become available in Japan. These vasodilators may improve exercise tolerance, hemodynamics, activities of daily life, and the life span. In this article, we review an endothelin-receptor antagonist and phosphodiesterase type 5 inhibitor recently approved as treatment modalities for pulmonary hypertension in Japan.
Kamata
Yasuyuki
Y
Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University.
Iwamoto
Masahiro
M
Minota
Seiji
S
D003240:Connective Tissue Diseases / Q000150:complications*; D065128:Endothelin Receptor Antagonists; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*
D065128:Endothelin Receptor Antagonists; D010726:Phosphodiesterase Inhibitors